Biocon Limited (NSE: BIOCON) announced that its Pertuzumab biosimilar has become the first biosimilar to secure a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval recommendation under the new tailored clinical approach marks a significant milestone for Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited. The biosimilar, marketed under the brand name Pebrilzo®, is indicated for the treatment of HER2-positive breast cancer across multiple disease stages.

Extensive Clinical and Analytical Validation

The positive CHMP opinion follows a comprehensive review of the marketing authorization application submitted by Biocon Biologics Ireland Limited. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Pebrilzo® is highly similar to the reference biologic, with no clinically meaningful differences in quality, safety, or efficacy.

Expanding Access to Biologic Therapies

Shreehas Tambe, CEO & Managing Director of Biocon, said: “The positive CHMP opinion for our Pertuzumab biosimilar marks an important step toward expanding access to biologic therapies for patients with HER2-positive breast cancer in Europe.” This approval reflects an important milestone in the evolution of biosimilar science and greater regulatory confidence on advanced analytical and clinical pharmacology evidence to establish biosimilarity.

As the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA’s tailored clinical development approach, this approval is a testament to Biocon’s commitment to providing affordable, life-changing medicines to patients worldwide.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 44% of its 52-week range with RSI at 35. In other words, neither side has a clear edge right now. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Biocon Limited (NSE: BIOCON) has announced the signing of a 10-year supply contract for Pertuzumab in Brazil, marking a significant milestone in advancing HER2-positive breast cancer therapy. The contract was signed with Bahiafarma and Bionovis, under Brazil’s Productive Development Partnership (PDP) program. The consortium received 100% allocation under Brazil’s 10-year PDP program for Pertuzumab, providing exclusive access to Brazil’s public healthcare market.

Strategic Partnership

Shreehas Tambe, CEO & Managing Director of Biocon, emphasized the transformative potential of strong partnerships in building local capabilities and expanding access to affordable medicines. This contract enables Biocon to reach more patients with HER2-positive breast cancer and address an important healthcare need at scale.

Market Impact

The PDP framework supports the long-term adoption of Biocon’s product within Brazil’s public oncology network. The product will undergo phased localization in Brazil in the mid to long term, ensuring sustainable access to this important cancer therapy. This partnership also contributes to Brazil strengthening its capacity to produce essential medicines for its Unified Health System (SUS).

Future Prospects

As part of the PDP, Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period. This agreement not only supports better patient outcomes but also helps build a stronger, more resilient healthcare ecosystem in Brazil.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 18 of recent sessions versus 12 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Biocon Limited (BIOCON) has reported its Q1 FY27 earnings, showcasing a 9% increase in total revenue to ₹4,391 crore. The company’s biosimilars segment has been the primary driver of this growth, with revenues up 16% year-on-year to ₹2,855 crore. The generics segment also contributed positively with a 21% YoY revenue increase to ₹760 crore. However, the services segment faced challenges, with revenues declining 16% to ₹736 crore.

Biosimilars Segment Performance

The biosimilars division has shown robust performance, with EBITDA up 10% YoY to ₹728 crore. The R&D spend increased to 7% of revenue, reflecting the company’s focus on sustaining its growth momentum. The segment’s EBITDA margin stood at 25%, driven by successful market launches and operational efficiencies.

Generics Segment Insights

The generics segment continued to perform well, driven by the generic liraglutide, which saw strong uptake across multiple markets, including the USA. The EBITDA margin improved significantly, up by over 250 basis points QoQ to 7%.

Services Segment Challenges

The services segment faced headwinds due to lower offtake from a key biologics client and forex hedge losses. Despite cost optimization initiatives, revenues declined 16% to ₹736 crore. The company remains optimistic about the second half of FY27, with a focus on cost-competitiveness and strategic collaborations.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon rises 11.2% over three months, with buying pressure holding steady. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 81% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 11.2% in three months on 15.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Biocon Limited.